Preclinical studies have currently been investigating biomaterial-alone therapies or biomaterials loaded with therapeutics as potential treatment options for myocardial infarction (MI) and peripheral artery disease (PAD). Other therapeutics, like microribonucleic acids (miRNAs) or exosomes, also show promise as factors to be delivered with a biomaterial.
SUMMARY
As the number of global deaths attributed to cardiovascular disease continues to rise, viable treatments for cardiovascular events such as myocardial infarction or conditions like peripheral artery disease are critical.
Recent studies investigating injectable biomaterials have shown promise in promoting tissue regeneration and functional improvement, and in some cases, incorporating other therapeutics further augments the beneficial effects of these biomaterials. In this review, we aim to emphasize the advantages of acellular injectable biomaterial-based therapies, specifically material-alone approaches or delivery of acellular biologics, in regard to manufacturability and the capacity of these biomaterials to regenerate or repair diseased tissue. We will focus on design parameters and mechanisms that maximize therapeutic efficacy, particularly, improved functional perfusion and neovascularization regarding peripheral artery disease and improved cardiac function and reduced negative left ventricular remodeling post-myocardial infarction. We will then discuss the rationale and challenges of designing new injectable biomaterial-based therapies for the clinic. showing that mechanical properties of a material are Hernandez and Christman
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A P R I L 2 0 1 7 : 2 1 2 -2 6 indeed important; however, these results could be related to the corresponding cellular response.
Although not typically a concern with naturally derived injectable hydrogels, one should also ensure that a material is not too stiff so that it negatively affects diastolic function.
Similar to chemistry and mechanical properties, Obviating the need for an invasive surgery with general anesthesia has, however, resulted in the majority of injectable therapeutics, including biomaterials, being delivered via catheter-based approaches in clinical trials. For catheter delivery, the material must be hemocompatible given embolization risks since the material is injected into a coronary with an infusion approach and is known to leak into the LV chamber with transendocardial injections.
In addition, the material must be designed to have appropriate gelation kinetics to travel through a long, small-diameter catheter (typically 27-gauge) and gel in the infarct, but not in the blood stream. The rapid gelation and/or lack of hemocompatibility have prevented most injectable biomaterials from being delivered with these more translationally relevant methods. For instance, an alginate formulation that is being studied in HF patients was not initially designed for catheter delivery and, therefore, must be delivered via an invasive surgical approach (7, 12 (31) looked at the effects of interstitial spread with poly(ethylene glycol)-based hydrogels and did not discover changes to action potential propagation with high spreading materials. However, significant delays as well as a reduction in gap junction density were found with materials that were quick gelling and formed a bolus, suggesting that they may be a potential substrate for arrhythmias (31). This study was only done in rats, though, and additional studies are Hernandez and Christman
reach the infarct zone due to microvascular occlusions. Another significant possibility is that cells do not adhere readily to alginate, and thus it has minimal bioactivity, which could have resulted in a lack of improvements. In the AUGMENT-HF trial, significantly increased peak VO 2 levels and 6-min walk test distance were seen at 3, 6, and 12 months after intervention via 10 to 19 0.3-ml intramyocardial injections through a limited left thoracotomy approach compared with standard medical therapy alone (7, 12) . 
Hernandez and Christman J A C C : B A S I C T O T R A N S L A T I O N A L S C I E N C E V O L . 2 , N O . 2 , 2 0 1 7
Injectable Biomaterials for PAD and MI 
